Investors

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities.
More>>
Featured Reports
Fact Sheet - PDF Fact Sheet
2014 Annual Report on Form 10-K  - PDF 2014 Annual Report on Form 10-K
OSUR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$6.29
Change (%) Stock is Down 0.27 (0.00%)
Volume1,107,089
Data as of 02/10/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
02/03/16OraSure Announces Record Revenues for Full-Year and Fourth Quarter 2015
BETHLEHEM, Pa., Feb. 03, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the full-year and fourth quarter ended December 31, 2015. Financial Highlights Consolidated net revenues for the fourth quarter of 2015 were $32.4 million, a 13% increase from the fourth quarter of 2014. Consolidated net revenues for the year ended December 31, 2015 ... 
Printer Friendly Version
01/13/16OraSure Technologies Earnings Conference Call Invitation
2015 Fourth Quarter Earnings Conference Call Wednesday, February 3, 2016, 5:00 p.m. ET BETHLEHEM, Pa., Jan. 13, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering 2015 fourth quarter financial results, 2016 first quarter financial guidance and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, February 3, 2016.   February 3, 2016 Schedule 4:00 p.m. ET 2015 fourth ... 
Printer Friendly Version
12/08/15DNA Genotek Inc. Appoints Microbiome Data Scientist as Advisor
Dan Knights, PhD, Brings Deep Experience in Microbiome Analysis and Biomarker Discovery OTTAWA, ON, December 8, 2015. DNA Genotek, a leading provider of sample collection kits and end-to-end services for human genomics, microbiome and infectious disease, today announced Dan Knights, PhD – an expert in machine learning and microbiome analysis – as a scientific advisor to the company. Dr. Dan Knights is a computational microbiologist and a leading authority in the application of machine learning... 
Printer Friendly Version
11/10/15OraSure Technologies to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
BETHLEHEM, Pa., Nov. 10, 2015 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Canaccord Genuity Medical Technology & Diagnostic Forum in New York City, New York. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on November 19, 2015, at approxima... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
05/17/16
OraSure Technologies, Inc. Annual Shareholder Meeting
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources



Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet